Product nameAnti-ITPA antibody [EPR8780]
See all ITPA primary antibodies
DescriptionRabbit monoclonal [EPR8780] to ITPA
Tested applicationsSuitable for: IHC-P, WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IP
Species reactivityReacts with: Human
Synthetic peptide within Human ITPA aa 100-200. The exact sequence is proprietary.
- Human breast carcinoma tissue; HeLa, HepG2, Jurkat and K562 cell lysates.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product was previously labelled as Inosine triphosphate pyrophosphatase
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab134937 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. For antigen retrieval: heat up to 98°C, below boiling, and then let cool for 10-20 min. Use of an HRP/AP polymerized secondary antibody is recommended.|
|WB||1/1000 - 1/10000. Predicted molecular weight: 21 kDa.|
FunctionHydrolyzes ITP and dITP to their respective monophosphate derivatives. Xanthosine 5'-triphosphate (XTP) is also a potential substrate. May be the major enzyme responsible for regulating ITP concentration in cells.
Tissue specificityUbiquitous. Highly expressed in heart, liver, sex glands, thyroid and adrenal gland.
Involvement in diseaseDefects in ITPA are the cause of inosine triphosphate pyrophosphohydrolase deficiency (ITPA deficiency) [MIM:147520]. It is a common inherited trait characterized by the abnormal accumulation of inosine triphosphate (ITP) in erythrocytes and also leukocytes and fibroblasts. The pathological consequences of ITPA deficiency, if any, are unknown. However, it might have pharmacogenomic implications and be related to increased drug toxicity of purine analog drugs. Three different human populations have been reported with respect to their ITPase activity: high, mean (25% of high) and low activity. The variant Thr-32 is associated with complete loss of enzyme activity, may be by altering the local secondary structure of the protein. Heterozygotes for this polymorphism have 22.5% of the control activity: this is consistent with a dimeric structure of the enzyme.
Sequence similaritiesBelongs to the HAM1 NTPase family.
- Information by UniProt
- C20orf37 antibody
- dJ794I6.3 antibody
- HLC14-06-P antibody
All lanes : Anti-ITPA antibody [EPR8780] (ab134937) at 1/1000 dilution
Lane 1 : Jurkat cell lysate
Lane 2 : HepG2 cell lysate
Lane 3 : HeLa cell lysate
Lane 4 : K562 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Standard HRP labelled goat anti-rabbit at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 21 kDa
Immunohistochemical analysis of paraffin-embedded, formalin-fixed Human breast carcinoma tissue, labelling ITPA using ab134937 at a 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab134937 has not yet been referenced specifically in any publications.